PloS one

Asia-Pacific journal of oncology nursing

investigational new drugs

nanomedicine (london, england)

International journal of environmental research and public health

Environmental science & technology

International journal of cancer

health information and libraries journal

JAMA

the journal of pathology

blood advances

Cell reports

molecular & cellular proteomics : mcp

indian journal of medical ethics

Alternative therapies in health and medicine

Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)

cancer

Practical radiation oncology

gynecologic oncology

experimental and therapeutic medicine

Annals of oncology : official journal of the European Society for Medical Oncology

International journal of biological sciences

indonesian journal of biotechnology

american journal of perinatology

journal of gynecologic oncology

expert opinion on investigational drugs

cellular signalling

general physiology and biophysics

nature neuroscience

Journal of ovarian research

[1] MicroRNA-21 as a biomarker for ovarian cancer detection

[2] Risk of Endometriosis and Subsequent Ovary and Breast Cancers in Nurses: A Population-Based Cohort Study in Taiwan.

[3] Defining the molecular evolution of extrauterine high grade serous carcinoma.

[4] Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.

[5] Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.

[6] ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

[7] A preliminary report: genistein attenuates cerebral ischemia injury in ovariectomized rats via regulation of the PI3K-Akt-mTOR pathway.

[8] AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells.

[9] The Positive Fate of Biochar Addition to Soil in the Degradation of PHBV-Silver Nanoparticle Composites.

[10] Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.

[11] Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients.

[12] GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.

[13] TRIM59 Is a Novel Marker of Poor Prognosis and Promotes Malignant Progression of Ovarian Cancer by Inducing Annexin A2 Expression.

[14] Increased temperature-related adeno-associated virus vectors transduction of ovarian cancer cells - essential signatures of AAV receptor and heat shock proteins.

[15] Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein.

[16] Metabolic Factors Contribute to T-cell Inhibition in the Ovarian Cancer Ascites.

[17] Multicenter Experience with Neurally Adjusted Ventilatory Assist in Infants with Severe Bronchopulmonary Dysplasia.

[18] RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.

[19] Interferon-complement loop in transplant-associated thrombotic microangiopathy.

[20] Phase 2 trial of montelukast for prevention of pain in sickle cell disease.

[21] Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.

[22] Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.

[23] The American Board of Radiology Focused Practice Recognition in Brachytherapy (FPRB) Program: Opportunities lost, lessons learned, and future implications.

[24] REALISE-ing their potential?: Implementing local library projects to support evidence-based health care.

[25] Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.

[26] roles of micrornas in ovarian cancer tumorigenesis: two decades later, what have we learned?

[27] right place, right time: preferences of women with ovarian cancer for delivery of cam education

[28] effect of zhenwu decoction combined with neoadjuvant chemotherapy on malignant characteristics of cancer cells in ovarian cancer

[29] cáncer de ovario en el instituto nacional de oncología y radiobiología de cuba: 2001 a 2005 ovarian cancer at the national institute of oncology and radiobiology of cuba: 2001-2005

[30] gene co-expression analyses differentiate networks associated with diverse cancers harbouring tp53 missense or null mutations

[31] clinical significance of detecting cea, ca199, afp, hcg, ca153, ca125 in postoperative treatment of patients with ovarian cancer

[32] case of ovarian cancer in a woman with undiagnosed graves’ disease: a case report and review of the literature

[33] pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted ecoflex® nanoparticles for docetaxel delivery in ovarian cancer

[34] evidence of differential effects of vitamin d receptor variants on epithelial ovarian cancer risk by predicted vitamin d status

[35] utilization of wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas

[36] ovarian cancer after in vitro fertilization

[37] prawidłowa ciąża u pacjentki po operacji oszczędzającej płodność z powodu raka jajnika w stopniu ic i guza o granicznej złośliwości po stronie przeciwnej

[38] natural killer cell-based immunotherapy in gynecologic malignancy: a review

[39] avastin in clinical chemotherapy of malignant tumors

[40] seldi-tof ms profiling of plasma proteins in ovarian cancer

[41] altered expression pattern of topoisomerase iiα, in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy

[42] effect of metformin on the prognosis of diabetic patients combined with gynecologic cancer: a meta-analysis

[43] clinical and survival impact of fdg pet in patients with suspicion of recurrent ovarian cancer: a 6-year follow-up

[44] overexpression of traf4 gene in ovarian cancer samples and association with metastasis and poor prognosis in patients

[45] proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer

[46] diagnosis, surgical treatment, and management of borderline ovarian surface epithelial neoplasms: report of 2 cases and review of literature

[47] leptomeningeal carcinomatosis and bilateral internal auditory canal metastases from ovarian carcinoma

[48] ocena wybranych parametrów klinicznych i biochemicznych u kobiet chorych na raka jajnika w okresie 5-letniej obserwacji

[49] diagnostic and prognostic importance of venous thromboembolism in ovarian cancer

[50] local renin angiotensin system in the reproductive system: a review of literature

[51] centralization of ovarian cancer surgery: do patients benefit?

[52] a case report of long term bevacizumab treatment in multiresistant ovarian cancer

[53] estrogen biosynthesis and action in ovarian cancer

[54] medical image of the week: bronchial clot removal via cryotherapy

[55] cellular, molecular consequences of peroxisome proliferator- activated receptor-δ activation in ovarian cancer cells

[56] brain metastasis in advanced serous borderline tumor of the ovary: a case presentation

[57] hm015k, a novel silybin derivative, multi-targets metastatic ovarian cancer cells and is safe in zebrafish toxicity studies

[58] comparative gene expression analysis of lymphocytes treated with exosomes derived from ovarian cancer and ovarian cysts

[59] Coping Strategies among Malaysian Women with Recurrent Ovarian Cancer: A Qualitative Study.

[60] Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers

[61] Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapy.

[62] Fish intake and ovarian cancer risk: a meta-analysis of 15 case-control and cohort studies.

[63] Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.

[64] Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.

[65] Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer via a Multi-omics Integrative Analysis.

[66] Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study.

[67] Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study.

[68] [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].

[69] MicroRNA-936 targets FGF2 to inhibit epithelial ovarian cancer aggressiveness by deactivating the PI3K/Akt pathway.

[70] Meeting report from the 2018 12th Biennial Ovarian Cancer Research Symposium detection and prevention of ovarian cancer.

[71] Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts.

[72] EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.

[73] Phytochemicals in the treatment of ovarian cancer.

[74] MicroRNA-21 as a biomarker for ovarian cancer detection

[75] Patterns of ovarian cancer and uterine cancer mortality and incidence in the contiguous USA.

[76] Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer

[77] Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells

[78] Discovery of HB-EGF binding peptides and their functional characterization in ovarian cancer cell lines

[79] Prior uterine myoma and risk of ovarian cancer: a population-based case-control study.

[80] Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.

[81] Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.

[82] [Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

[83] Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.

[84] Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.

[85] Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC)

[86] Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.

[87] Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.

[88] ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

[89] AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells.

[90] Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?

[91] Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study

[92] Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment.

[93] Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.

[94] Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients.

[95] Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR

[96] Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells

[97] NOS1 upregulates ABCG2 expression contributing to DDP chemoresistance in ovarian cancer cells

[98] P-MAPA and IL-12 Differentially Regulate Proteins Associated with Ovarian Cancer Progression: A Proteomic Study.

[99] Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.

[100] A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles.

[101] Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells.